Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Isocitrate dehydrogenase 1 (IDH1) mutations are common in cancers, affecting cellular metabolism and redox balance.
• IDH1 mutations lead to reduced nicotinamide adenine dinucleotide phosphate (NADPH) and impaired glutathione synthesis.
• Nuclear factor erythroid-2-related factor 2 (Nrf2) is a key regulator of antioxidant responses.

Purpose of the Study:

• To investigate the role of IDH1 mutations in regulating Nrf2-mediated signaling pathways in fibrosarcoma.
• To explore the impact of IDH1 inhibition on cancer cell behavior and immune evasion.

Main Methods:

• Utilized siRNA to knockdown IDH1 in HT1080 fibrosarcoma cells.
• Assessed Nrf2 stabilization, antioxidant gene expression, reactive oxygen species (ROS) production, and cell migration.
• Employed small molecule inhibitors targeting IDH1 R132 mutations.
• Analyzed the expression of programmed death-ligand 1 (PD-L1).

Main Results:

• IDH1 knockdown inhibited Nrf2 stabilization and reduced antioxidant gene expression, favoring cancer progression.
• IDH1 inhibition decreased ROS production and impaired cell migration and colony formation.
• Targeting IDH1 R132 mutations suppressed cell migration and colony formation.
• IDH1 and Nrf2 modulate PD-L1 expression, contributing to immune evasion.

Conclusions:

• IDH1 mutations play a critical role in regulating Nrf2-mediated antioxidant defense and promoting malignant phenotypes.
• Targeting the IDH1-Nrf2 axis presents a potential therapeutic strategy for IDH1-mutant cancers.
• This axis influences immune evasion via PD-L1 modulation, offering insights for immunotherapy development.